Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 239

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

Open access
Prockop, Susan, Doubrovina, Ekaterina, Suser, Stephanie, Heller, Glenn, Barker, Juliet, Dahi, Parastoo, Perales, Miguel A., Papadopoulos, Esperanza, Sauter, Craig, Castro-Malaspina, Hugo, Boulad, Farid, Curran, Kevin J., Giralt, Sergio, Gyurkocza, Boglarka, Hsu, Katharine C., Jakubowski, Ann, Hanash, Alan M., Kernan, Nancy A., Kobos, Rachel, Koehne, Guenther, Landau, Heather, Ponce, Doris, Spitzer, Barbara, Young, James W., Behr, Gerald, Dunphy, Mark, Haque, Sofia, Teruya-Feldstein, Julie, Arcila, Maria, Moung, Christine, Hsu, Susan, Hasan, Aisha, O’Reilly, Richard J. · 2020 · Journal of Clinical Investigation

Abstract

BACKGROUNDAdoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.METHODSWe developed a third-party, allogeneic, off-the-shelf bank of 330 GMP-grade EBV-CTL lines from specifically consented healthy HCT donors. We treated 46 recipients of HCT (n = 33) or SOT (n = 13) with established EBV-PTLD, who had failed rituximab therapy, with third-party EBV-CTLs. Treatment cycles consisted of 3 weekly infusions of EBV-CTLs and 3 weeks of observation.RESULTSEBV-CTLs did not induce significant toxicities. One patient developed grade I skin graft-versus-host disease. Complete remission (CR) or sustained partial remission (PR) was achieved in 68% of HCT recipients and 54% of SOT recipients. For patients who achieved CR/PR or stable disease after cycle 1, one year overall survival was 88.9% and 81.8%, respectively. In addition, 3 of 5 recipients with POD after a first cycle who received EBV-CTLs from a different donor achieved CR or durable PR (60%) and survived longer than 1 year. Maximal responses were achieved after a median of 2 cycles.CONCLUSIONThird-party EBV-CTLs of defined HLA restriction provide safe, immediately accessible treatment for EBV-PTLD. Secondary treatment with EBV-CTLs restricted by a different HLA allele (switch therapy) can also induce remissions if initial EBV-CTLs are ineffective. These results suggest a promising potential therapy for patients with rituximab-refractory EBV-associated lymphoma after transplantation.TRIAL REGISTRATIONPhase II protocols (NCT01498484 and NCT00002663) were approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center, the FDA, and the National Marrow Donor Program.FUNDINGThis work was supported by NIH grants CA23766 and R21CA162002, the Aubrey Fund, the Claire Tow Foundation, the Major Family Foundation, the Max Cure Foundation, the Richard "Rick" J. Eisemann Pediatric Research Fund, the Banbury Foundation, the Edith Robertson Foundation, and the Larry Smead Foundation. Atara Biotherapeutics licensed the bank of third-party EBV-CTLs from Memorial Sloan Kettering Cancer Center in June 2015.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci121127

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 239

Metadata

Authors
Prockop, S., Doubrovina, E., Suser, S., Heller, G., Barker, J., Dahi, P., Perales, M. A., Papadopoulos, E., Sauter, C., Castro-Malaspina, H., Boulad, F., Curran, K. J., Giralt, S., Gyurkocza, B., Hsu, K. C., Jakubowski, A., Hanash, A. M., Kernan, N. A., Kobos, R., Koehne, G., Landau, H., Ponce, D., Spitzer, B., Young, J. W., Behr, G., Dunphy, M., Haque, S., Teruya-Feldstein, J., Arcila, M., Moung, C., Hsu, S., Hasan, A., & O’Reilly, R. J.
Venue
Journal of Clinical Investigation
Published
2020-01-06
Volume
130
Issue
2
Pages
733-747
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2986046464
Cited by
239
References
2
FWCI
8.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. https://app.cochat.ai/papers/10.1172/jci121127
The paper
Prockop, S., Doubrovina, E., Suser, S., Heller, G., Barker, J., Dahi, P., Perales, M. A., Papadopoulos, E., Sauter, C., Castro-Malaspina, H., Boulad, F., Curran, K. J., Giralt, S., Gyurkocza, B., Hsu, K. C., Jakubowski, A., Hanash, A. M., Kernan, N. A., Kobos, R., . . . O’Reilly, R. J. (2020). Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. Journal of Clinical Investigation. https://doi.org/10.1172/jci121127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.